Septerna, Inc.

Septerna, Inc. (SEPN) Market Cap

Septerna, Inc. has a market capitalization of $1.63B.

Price: $36.17

▲ 0.37 (1.03%)

Market Cap: 1.63B

NASDAQ · time unavailable

CEO: Jeffrey T. Finer

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2024-10-25

Website: https://septerna.com

Septerna, Inc. (SEPN) - Company Information

Market Cap: 1.63B|Sector: Healthcare

Company Profile

Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.

Analyst Sentiment

92%
Strong Buy

From 7 Active Polls

1Y Forecast: $50.00

▲ +38.2% Potential Upside

Consensus Target Metrics

Low Bound

$35

Median

$53

High Bound

$60

Average

$50

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$50.00
▲ +38.24% Upside
Low Target
$35.00
-3% Risk
Median Target
$52.50
45% Mid
High Target
$60.00
66% Max
Consensus
Buy
7 / 7 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

valuation & financial ratiosdetailed financials

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,6301,0761,234834467254742899899
Enterprise Value ($M)1,5821,0271,13753830269529836780
Price to Earnings Ratio (P/E)-44.92-31.13-28.7325.51-4.70-2.96-8.97-10.95-13.67
Price/Earnings-to-Growth Ratio (PEG)—-3.12-2.350.00—-0.90-0.44—-0.82
Price to Sales Ratio (P/S)22.5640.5551.1638.803922.911161.633498.015107.162429.35
Price to Book Ratio (P/B)4.282.843.232.151.240.641.77-10.28-13.26
Price to Free Cash Flow Ratio (P/FCF)15.25-40.64-81.974.94-22.95-10.72-34.38-51.68-68.43
Enterprise Value to Sales (EV/Sales)—38.7247.1425.042538.54316.802494.614749.112108.00
Enterprise Value to EBITDA (EV/EBITDA)-30.35-130.35-110.10-56.74-12.36-3.29-25.87-41.18-48.10
Debt to Equity Ratio0.930.060.060.060.070.060.06-0.29-0.18
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-34.0%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for SEPN. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SEPTERNA INC (SEPN) — Investment Overview

🧩 Business Model Overview

I don’t have enough reliable, company-specific information in this chat to produce a high-conviction, evergreen investment thesis for SEPTERNA INC (SEPN) without risking inaccuracies about its value chain, revenue mix, moats, and competitors. If you share (or paste) a short company description from the latest 10-K/10-Q (or the investor deck)—especially the business segment(s) and how it makes money—I can convert it into the requested institutional-style research note.

💰 Revenue Streams & Monetisation Model

Please provide: (1) primary products/services, (2) how revenue is recognized (sales vs. subscriptions vs. usage fees vs. royalties), and (3) whether revenue is recurring or transactional.

🧠 Competitive Advantages & Market Positioning

Please provide: (1) top 2–3 competitors you consider most relevant (or the company’s stated peer set), and (2) the key differentiators the company cites (e.g., regulatory approvals, IP, workflow integration, cost advantage, distribution).

🚀 Multi-Year Growth Drivers

Please provide: (1) the target customer segment(s), (2) the demand drivers the company highlights (regulatory, market adoption, capacity expansion, utilization), and (3) geographic scope (if applicable).

⚠ Risk Factors to Monitor

Please provide: (1) any dependency on partners, supply chain, major customers, or reimbursement/regulatory pathways, and (2) whether the business is capital-intensive (and why).

📊 Valuation & Market View

Once the business model is confirmed, I will describe how markets typically value that specific sector (e.g., EV/EBITDA, P/S, or clinical-stage probabilistic frameworks) and what fundamental drivers most move multiples.

🔍 Investment Takeaway

Reply with the company’s segment overview + revenue model + peer set, and I will produce the full high-conviction HTML investment summary with clearly identified moats tailored to the correct industry framework.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SEPN.

businesswire.com•2026-06-08

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, sel.

seekingalpha.com•2026-05-13

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

zacks.com•2026-05-11

Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.

globenewswire.com•2026-05-11

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026

globenewswire.com•2026-05-05

Septerna to Present at Bank of America Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.

globenewswire.com•2026-04-13

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers

zacks.com•2026-03-09

Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.64 per share a year ago.

globenewswire.com•2026-03-09

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026  Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.

globenewswire.com•2026-03-01

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily  Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026 Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif.

globenewswire.com•2026-02-24

Septerna to Present at TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.

defenseworld.net•2026-02-22

Septerna (NASDAQ:SEPN) Stock Price Down 5.9% on Insider Selling

Septerna, Inc. (NASDAQ: SEPN - Get Free Report)'s stock price traded down 5.9% during trading on Friday after an insider sold shares in the company. The company traded as low as $26.15 and last traded at $25.4950. 11,134 shares changed hands during trading, a decline of 96% from the average session volume of 291,271 shares. The

globenewswire.com•2026-02-10

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company's Board of Directors granted an inducement award to Mark A. Wilson, Septerna's Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan. The award was granted as an inducement material to Mr. Wilson's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com•2026-02-10

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, taking place February 27-March 2, 2026, in Philadelphia.

globenewswire.com•2026-01-08

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A.

globenewswire.com•2025-12-17

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

Related Companies in Healthcare

MINERALYS THERAPEUTICS INC (MLYS)

Healthcare

$1.63B

Mkt Cap

UROGEN PHARMA LTD (URGN)

Healthcare

$1.64B

Mkt Cap

NOVOCURE LTD (NVCR)

Healthcare

$1.65B

Mkt Cap

TAYSHA GENE THERAPIES INC (TSHA)

Healthcare

$1.61B

Mkt Cap

INNOVIVA INC (INVA)

Healthcare

$1.66B

Mkt Cap

HARROW INC (HROW)

Healthcare

$1.60B

Mkt Cap

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SEPN (2026-03-31, Q1) reported Revenue of $26.52M and Net Income of -$8.64M (EPS -$0.19). YoY, Revenue rose strongly from $0.219M in 2025-03-31 to $26.52M (+~11,999%); Net Income deteriorated from -$21.48M to -$8.64M (improvement of ~60% vs prior-year). QoQ, Revenue increased from $24.12M in 2025-12-31 to $26.52M (+~9.9%), while Net Income loss widened from -$10.74M to -$8.64M (loss improved ~19.6%). Profitability remained weak: operating margin was -50.1% in Q1 2026, still deeply negative, but operating performance improved materially versus Q4 2025 where margins were -66.4%. Cash flow quality is mixed. Operating Cash Flow was -$25.63M and Free Cash Flow was -$26.47M, reflecting ongoing cash burn despite the improvement in earnings vs last year/quarter. Balance sheet resilience looks solid: cash & short-term investments were $347.40M and net cash remained positive (-$48.5M net debt, i.e., net cash). There was no dividend activity; buybacks were not reported. Total shareholder return is likely strong given momentum: the stock is up +336.23% over 1 year (price momentum >20% materially boosts the score)."

Revenue Growth

Strong

Revenue grew QoQ from $24.12M (2025-12-31) to $26.52M (2026-03-31, +~9.9%) and surged YoY from $0.219M (2025-03-31) to $26.52M (+~12,000%).

Profitability

Fair

Net Income remains negative but improved: from -$10.74M (Q4 2025) to -$8.64M (Q1 2026, loss improved ~19.6%) and from -$21.48M (Q1 2025) to -$8.64M (improvement ~60%). Operating margin stayed deeply negative (Q1 2026: -50.1%), though it improved vs -66.4% in Q4 2025.

Cash Flow Quality

Caution

Despite earnings improvement YoY/QoQ, cash flow was still negative: Operating Cash Flow -$25.63M and Free Cash Flow -$26.47M in Q1 2026. No dividends or buybacks were reported.

Leverage & Balance Sheet

Good

Strong liquidity with cash & short-term investments of $347.40M. Balance sheet equity is stable-high at $378.46M. Net debt is negative (net cash position); leverage appears low with total assets $569.69M.

Shareholder Returns

Strong

High 1-year price momentum (+336.23%) meaningfully boosts total return potential. Dividend yield is 0 and buybacks are not shown, so return is primarily price-driven.

Analyst Sentiment & Valuation

Neutral

Analyst consensus target ($39) is above the current price ($26.13), implying upside, but the business is still loss-making with negative margins and negative FCF.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

RevenueEarningsP/E RatioSharesDebtMargin %

Fundamentals Overview

Loading fundamentals overview...

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for SEPN.

SEC EDGAR Live Feed
10-K
Latest Annual Report
Filed: Mar 9, 2026
→
10-Q
Latest Quarterly Report
Filed: May 11, 2026
→
🔍 View Full Historical 10-K & 10-Q Archive on SEC EDGAR
Loading financial data and tables...
📁

SEC Filings (SEPN)

© 2026 Stock Market Info — Septerna, Inc. (SEPN) Financial Profile